DOCSLIB.ORG

In Re INSYS Therapeutics, Inc. Securities Litigation 17-CV-01954

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
In Re INSYS Therapeutics, Inc. Securities Litigation 17-CV-01954 Case 1:17-cv-01954-PAC Document 30 Filed 10/27/17 Page 1 of 120 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK IN RE INSYS THERAPEUTICS, INC. Civil Action No. 1:17-cv-01954-PAC SECURITIES LITIGATION SECOND AMENDED CLASS ACTION COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS Case 1:17-cv-01954-PAC Document 30 Filed 10/27/17 Page 2 of 120 TABLE OF CONTENTS SUMMARY OF THE ACTION..................................................................................................... 1 JURISDICTION AND VENUE ..................................................................................................... 4 THE PARTIES................................................................................................................................ 4 I. Lead Plaintiff........................................................................................................................ 4 II. Defendants............................................................................................................................ 5 A. Insys Therapeutics, Inc..................................................................................................... 5 B. The Individual Defendants............................................................................................... 5 STATEMENT OF FACTS ........................................................................................................... 11 I. Company Background........................................................................................................ 11 A. Insys’s Success Is Dependent on the Sale of Subsys, Its Only Product on the Market. 11 B. The Majority of Insys’s Revenue From Subsys Is Derived From Reimbursements Received From Third-Party Payers................................................................................ 13 C. Insys Closely Monitored Authorization and Reimbursement Rates Through Its Insurance Reimbursement Center. ................................................................................. 16 D. Insys Top Management Admittedly Monitors the Company’s Main Customers’ Inventory Levels Through Inventory Reports Received Directly From Customers...... 17 II. Third-Party Payers Cease Approving and/or Reimbursing for Off-Label Prescriptions of Subsys Upon Revelation of the Company’s Illegal Kickback Scheme.............................. 18 III. Defendants Institute a “Tone at the Top” to Engage in Accounting Manipulations in Order to Conceal the Company’s Declining Subsys Revenues.................................................... 23 A. Defendants Prematurely Recognize Revenue for Subsys Before It Was Sold to the End- User or the Right of Return Expired.............................................................................. 23 B. Defendants Fail to Properly Recognize Product Returns and Rebates, Which Could Not Be Reasonably Estimated Based on Insys’s Lengthy Return Policy............................. 25 IV. The Audit Committee of the Insys Board of Directors Commences an Internal Investigation of the Accounting Fraud............................................................................... 27 POST-CLASS PERIOD EVENTS ............................................................................................... 27 I. Insys Announces “Material” Restatements to the Company’s Interim Financial Statements Resulting from a “Tone at the Top” and Woeful Lack of Internal Controls. ..................... 27 II. The Chief Operating Officer, Chief Executive Officer, Interim Chief Executive Officer, Chief Medical Officer, and Chief Financial Officer of Insys “Resign” or Are “Terminated.” ..................................................................................................................... 28 DEFENDANTS’ MATERIALLY FALSE AND MISLEADING CLASS PERIOD STATEMENTS AND OMISSIONS ............................................................................................ 30 ii Case 1:17-cv-01954-PAC Document 30 Filed 10/27/17 Page 3 of 120 I. False and Misleading Statements in the May 7, 2015 Press Release and First Quarter Earnings Call ...................................................................................................................... 30 II. False and Misleading Statements in the 2015 First Quarter Form 10-Q............................ 31 A. False and Misleading Statements Concerning Compliance with Accounting Policies and GAAP............................................................................................................................. 32 B. False and Misleading Statements Concerning Insys’s Financial Statements and Compliance With GAAP ............................................................................................... 33 C. False and Misleading Statements Concerning Insys’s Internal Controls Over Financial Reporting........................................................................................................................ 34 III. False and Misleading Statements in the August 6, 2015 Press Release............................. 38 IV. False and Misleading Statements in the 2015 Second Quarter Report and Earnings Call. 39 A. False and Misleading Statements Concerning Compliance with Accounting Policies and GAAP............................................................................................................................. 39 B. False and Misleading Statements Concerning Insys’s Financial Statements and Compliance With GAAP ............................................................................................... 41 C. False and Misleading Statements Concerning Insys’s Internal Controls Over Financial Reporting........................................................................................................................ 42 V. False and Misleading Statements in the November 5, 2015 Press Release ....................... 43 VI. False and Misleading Statements in the 2015 Third Form 10-Q and Earnings Call.......... 44 A. False and Misleading Statements Concerning Compliance With Accounting Policies. 44 B. False and Misleading Statements Concerning Insys’s Financial Statements and Compliance With GAAP ............................................................................................... 46 C. False and Misleading Statements Concerning Insys’s Internal Controls Over Financial Reporting........................................................................................................................ 47 VII. False and Misleading Statements in the February 23, 2016 Press Release ........................ 48 VIII. False and Misleading Statements in the 2015 Annual Report and Earnings Call.............. 50 A. False and Misleading Statements Concerning Compliance With Accounting Policies. 50 B. False and Misleading Statements Concerning Insys’s Financial Statements and Compliance With GAAP ............................................................................................... 52 C. False and Misleading Statements Concerning Insys’s Internal Controls Over Financial Reporting........................................................................................................................ 55 IX. False and Misleading Statements in the April 28, 2016 Press Release .............................. 56 X. False and Misleading Statements in the 2016 First Quarter Form 10-Q and Earnings Call ..................................................................................................................................... 57 A. False and Misleading Statements Concerning Compliance With Accounting Policies. 58 iii Case 1:17-cv-01954-PAC Document 30 Filed 10/27/17 Page 4 of 120 B. False and Misleading Statements Concerning Insys’s Financial Statements and Compliance With GAAP ............................................................................................... 59 C. False and Misleading Statements Concerning Insys’s Internal Controls Over Financial Reporting........................................................................................................................ 61 XI. False and Misleading Statements in the August 3, 2016 Press Release and Earnings Call 63 XII. False and Misleading Statements in the 2016 Second Quarter Report .............................. 66 A. False and Misleading Statements Concerning Key Financial Metrics and Compliance With Internal Policies .................................................................................................... 66 B. False and Misleading Statements Concerning Insys’s Financial Statements and Compliance With GAAP ............................................................................................... 67 C. False and Misleading Statements Concerning Insys’s Internal Controls Over Financial Reporting........................................................................................................................ 68 XIII. False and Misleading Statements in the November 3, 2016 Press Release ....................... 70 XIV. False and Misleading Statements in the 2016 Third Quarter Form 10-Q .......................... 72 A. False and Misleading Statements Concerning Compliance With Accounting Policies. 73 B. False and Misleading Statements Concerning Insys’s Financial Statements and Compliance With GAAP ............................................................................................... 74 C. False and Misleading Statements Concerning Insys’s Internal Controls Over Financial Reporting.......................................................................................................................
Load more

Recommended publications
  • JUSTICE NEWS Opioid Manufacturer Insys Therapeutics Agrees to Enter
    JUSTICE NEWS Department of Justice Office of Public Affairs FOR IMMEDIATE RELEASE Wednesday, June 5, 2019 Opioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global Resolution of Criminal and Civil Investigations Company Admits Illegal Conduct Regarding Promotion of Subsys, a Powerful Opioid Painkiller Opioid manufacturer Insys Therapeutics agreed to a global resolution to settle the government’s separate criminal and civil investigations, the Department of Justice announced today. As part of the criminal resolution, Insys will enter into a deferred prosecution agreement with the government, Insys’s operating subsidiary will plead guilty to five counts of mail fraud, and the company will pay a $2 million fine and $28 million in forfeiture. As part of the civil resolution, Insys agreed to pay $195 million to settle allegations that it violated the False Claims Act. Both the criminal and civil investigations stemmed from Insys’s payment of kickbacks and other unlawful marketing practices in connection with the marketing of Subsys. Insys’s drug Subsys is a sublingual fentanyl spray, a powerful, but highly addictive, opioid painkiller. In 2012, Subsys was approved by the Food and Drug Administration for the treatment of persistent breakthrough pain in adult cancer patients who are already receiving, and tolerant to, around-the-clock opioid therapy. Today, the U.S. Attorney’s Office for the District of Massachusetts filed an Information charging Insys and its operating subsidiary with five counts of mail fraud. According to the charging document, from August 2012 to June 2015, Insys began using “speaker programs” purportedly to increase brand awareness of Subsys through peer-to-peer educational lunches and dinners.
    [Show full text]
  • Antiemetic/Antivertigo Agents – Dronabinol
    !ntiemetic/!ntivertigo !gents – dronabinol WA.PHAR.35 Antiemetic Antivertigo Agents Dronabinol Medical necessity Drug Medical Necessity Dronabinol (MARINOL®) Dronabinol may be considered medically necessary when: Dronabinol (SYNDROS®) Used for the treatment of ONE of the following 1. Anorexia associated with weight loss in adults with AIDS 2. Nausea and vomiting associated with chemotherapy in adults Clinical policy: Drug Clinical Criteria (Initial Approval) Dronabinol (MARINOL®) 1. Anorexia associated with weight loss in adults with AIDS Dronabinol (SYNDROS®) a. Defined by ONE of the following: i. Involuntary weight loss in adults of greater than 10% of pre-illness baseline body weight ii. BMI less than 20kg/m² in the absence of concurrent illness or medical condition other than AIDS that may cause weight loss b. History of failure, contraindication or intolerance to conventional therapies (e.g. megestrol (Megace®)) c. Dose limit: i. Marinol: 20mg per day ii. Syndros: 8.4mg twice daily 2. Prescribed by or in consultation with an HIV specialist Approve for 6 months Criteria (Reauthorization) 1. Continued diagnosis of AIDS wasting with continued wasting based on reduction of BMI 2. Documentation of positive clinical benefit Approve for 6 months Clinical Criteria (Initial Approval) 1. Nausea and vomiting associated with chemotherapy in adults a. Current diagnosis or cancer or history of cancer diagnosis in last year Policy: Dronabinol Last Updated 04/18/2018 1 b. Currently receiving chemotherapy or history of chemotherapy in the last year c. History of failure, contraindication or intolerance to conventional therapy (e.g. dexamethasone, ondansetron, aprepitant) 2. Dose limit: a. Marinol: 15mg/m² per dose for 4 to 6 doses per day b.
    [Show full text]
  • Medical Marijuana for People Living with HIV
    Medical Marijuana for People Living with HIV Jasjit Gill, B.S.Pharm., Pharm.D., R.Ph. Director of HIV Pharmacy Services – UC Denver School of Medicine Pharmacy Manager, Clinical Pharmacy Specialist Co-Chair, Vaccine Committee, Pharmacy & Therapeutics University of Colorado Hospital Infectious Disease Group Practice – Pharmacy Aurora, Colorado 1 Learning Objectives ♦ Review the laws and history of cannabinoids ♦ Describe the complexity of pharmacokinetic parameters of marijuana and how they may affect patient care ♦ Identify possible drug-drug interactions, side effects or adverse drug reactions with medical marijuana in healthcare 2 Marijuana Law ♦ Medical + recreational use is approved in 14 states ■ 34 states including District of Columbia, Guam, Puerto Rico and US Virgin Islands have medical marijuana laws ■ 12 states allow low THC, high CBD products for medical reasons in limited situations ■ Mariana Islands are the only territory to have recreational use only, no medical use http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx laws 3 A Brief History of Medicinal Marijuana ♦ Controlled Substance Act ♦ Scheduling ■ FDA ■ DHHS – Federal registry ■ NIDA ■ DEA ♦ Colorado ■ November 2000 Amendment 20 ■ 2010 the Colorado Legislature passed HB-1284 ■ November 2012 Amendment 64 4 Medical Marijuana in Healthcare ♦ China 2737 B.C ♦ No official US standards for herbals ♦ No German Commission E monograph ♦ US Pharmacopeia 1850 – 1942 ♦ 1937 Marijuana Tax Act ♦ Merck Index until 1950 ♦ Dronabinol Orphan Drug status 1985 ♦ No federally recognized use of marijuana 5 Dosage Forms ♦ Flowered Plant Dried (oral or inhaled) ♦ Hashish – Pure Resin ♦ Oil Hashish (5-10 times more potent) ♦ Capsule Marinol® , Nabilone® ♦ Buccal Spray Sativex® ♦ Solution Epidiolex® (purified CBD) ♦ Solution Syndros® (Dronabinol) 6 New Drugs approved by FDA ♦ Epidiolex (purified CBD) - (Schedule V) approved for add-on therapy for treatment of seizures related to Lennox-Gastaut and Dravet Syndrome.
    [Show full text]
  • A Critical Narrative Review of Medical Cannabis in Pediatrics Beyond Epilepsy, Part I: Background
    8 Review Article Page 1 of 8 A critical narrative review of medical cannabis in pediatrics beyond epilepsy, part I: background Jill S. Simonian1, Swathi Varanasi2, Anh Van Nguyen1, Joel P. Diaz-Fong3,4, George James Richards1, Jennifer Le1 1Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA; 2Emperor’s College of Traditional Oriental Medicine, Santa Monica, CA, USA; 3Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA, USA; 4Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA Contributions: (I) Conception and design: J Simonian; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Jill S. Simonian, PharmD. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, MC 0657, La Jolla, CA 92093, USA. Email: [email protected]. Abstract: In the past few decades, the use of marijuana, now commonly referred to as cannabis in the scientific community, has expanded globally to a myriad of medical conditions beyond epilepsy in pediatrics. In this comprehensive review, PubMed, Embase, and Clinicaltrials.gov (1966–May 2020) searches were performed using the key search terms cannabis, medical marijuana, cannabinoids, pediatrics, neuropsychiatric disorders, spasticity, pain, gastrointestinal disorders, and cancer. All article abstracts were evaluated for relevance. Only articles pertaining to cannabis were included.
    [Show full text]
  • ACNP 57Th Annual Meeting: Panels, Mini-Panels and Study Groups
    www.nature.com/npp ABSTRACTS COLLECTION ACNP 57th Annual Meeting: Panels, Mini-Panels and Study Groups Sponsorship Statement: Publication of this supplement is sponsored by the ACNP. Individual contributor disclosures may be found within the abstracts. Asterisks in the author lists indicate presenter of the abstract at the annual meeting. https://doi.org/10.1038/s41386-018-0265-8 Panel experiments were performed in 8-10-week-old male or female mice on a C57 background. 1. Dissecting the Contributions of Dopamine D1 and D2 Results: We observed dendritic atrophy in NAc D1-MSNs but Receptor-Expressing Neurons in Behaviors Dysregulated in not D2-MSNs in CSDS susceptible mice (P < 0.001). mRNAs of RhoA Neuropsychiatric Illness pathway molecules were significantly altered in D1-MSNs of CSDS susceptible mice (P < 0.05). Genetic overexpression of WT-RhoA in D1-MSNs induced dendritic atrophy and a susceptible outcome to 1.1 Dichotomous Structural Adaptations in Nucleus SSDS (P < 0.01), while DN-RhoA in D1-MSNs restored dendritic Accumbens Neuron Subtypes Underlie Stress Susceptibility complexity and caused a resilient outcome to CSDS (P < 0.05) compared to eYFP controls. RhoA (WT) in D1-MSNs caused reduced time grooming in splash test of female mice, reduced Mary Kay Lobo sucrose preference in male mice, and enhanced time immobile in forced swim test of both sexes (P < 0.05). Increased Egr3, the RhoA University of Maryland School of Medicine, Baltimore, Maryland, transcriptional regulator, in D2-MSNs promotes stress resiliency (P United States < 0.05) by preventing D2-MSN enhanced density of mushroom spines that occurs in stress susceptible mice (P < 0.01), without Background: Ventral striatum (nucleus accumbens-NAc) medium altering dendritic arbor.
    [Show full text]
  • CITY of DELRAY BEACH, Plaintiff
    Case 9:17-cv-81384-XXXX Document 1 Entered on FLSD Docket 12/21/2017 Page 1 of 148 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA Case No. _____-Civ-_________________ CITY OF DELRAY BEACH, ) ) Plaintiff, ) ) vs. ) ) PURDUE PHARMA L.P., CEPHALON, INC., ) DEMAND FOR JURY TRIAL TEVA PHARMACEUTICAL INDUSTRIES ) LTD., TEVA PHARMACEUTICALS USA, INC., ) ENDO INTERNATIONAL PLC, ENDO ) PHARMACEUTICALS, INC., JANSSEN ) PHARMACEUTICALS, INC., INSYS ) THERAPEUTICS, INC., MALLINCKRODT ) PLC, MALLINCKRODT PHARMACEUTICALS, ) AMERISOURCEBERGEN CORPORATION, ) CARDINAL HEALTH, INC. and McKESSON ) CORPORATION, ) ) Defendants. ) ) COMPLAINT FOR (1) VIOLATION OF THE FLORIDA DECEPTIVE AND UNFAIR TRADE PRACTICES ACT; (2) PUBLIC NUISANCE; (3) NEGLIGENCE; (4) UNJUST ENRICHMENT; AND (5) VIOLATION OF THE RACKETEER INFLUENCED AND CORRUPT ORGANIZATIONS ACT Case 9:17-cv-81384-XXXX Document 1 Entered on FLSD Docket 12/21/2017 Page 2 of 148 TABLE OF CONTENTS Page I. INTRODUCTION ...............................................................................................................1 II. PARTIES ...........................................................................................................................11 III. JURISDICTION AND VENUE ........................................................................................12 IV. FACTUAL ALLEGATIONS ............................................................................................13 A. Over the Course of More than Two Decades, the Manufacturing Defendants Misled the Public Regarding
    [Show full text]
  • IOA Two-Year Progress Report
    Two-Year Progress Report TABLE OF CONTENTS INTRODUCTION . 1 HISTORY OF THE IOA. 2 OPIOID BUSINESS RISKS: THE BUSINESS CASE FOR THE IOA . 5 IOA ENGAGEMENT STRATEGY AND COMPANIES . 8 KEY GOVERNANCE PROPOSALS FOR OPIOID SUPPLY CHAIN COMPANIES . 10 OPIOID BUSINESS RISKS BEYOND THE UNITED STATES . 17 APPENDIX 1 . 19 APPENDIX 2 . 20 APPENDIX 3 . 21 APPENDIX 4 . 22 APPENDIX 5 . 23 ENDNOTES . 27 INTRODUCTION This report summarizes the work of the Investors for • 26 negotiated settlements on governance issues Opioid Accountability (IOA) from July 1, 2017 to reached by companies and IOA members prior to a July 31, 2019. The IOA is a diverse global coalition vote of shareholders. of 57 members representing public, faith-based, labor, and sustainability funds, as well as investment • 4 negotiated settlements on governance issues managers, with $4 trillion in collective assets under reached by companies and IOA members following a management and advisement. The report covers the vote of shareholders. following topics: • 2 companies created a board level committee • The Business Case for the IOA; dedicated to oversight of opioids. • IOA Engagement Strategy & Companies; • 12 companies issued or committed to issue board risk reports. • Key Governance Proposals for Opioid Companies; • 10 companies adopted a misconduct clawback • Global Opioid Business Risks beyond the United policy. States; and • 3 companies agreed to separate the Chairman from • IOA Results by Company. CEO position. • 3 companies addressed executive compensation incentives by factoring in calculations of legal costs. Coalition Highlights by • 80 percent vote received for lobbying resolution filed the Numbers by IOA member United Church Funds at Mallinckrodt, • 57 members joined in fewer than two years.
    [Show full text]
  • Creating an Exception to the Learned Intermediary Doctrine in Light of the Opioid Crisis Max Roberts
    Fordham Urban Law Journal Volume 46 Number 3 Remodeling Sanctuary: Urban Immigration Article 6 in a New Era 2019 Weaning Drug Manufacturers Off Theiraink P iller: Creating an Exception to the Learned Intermediary Doctrine in Light of the Opioid Crisis Max Roberts Follow this and additional works at: https://ir.lawnet.fordham.edu/ulj Recommended Citation Max Roberts, Weaning Drug Manufacturers Off eiTh r Painkiller: Creating an Exception to the Learned Intermediary Doctrine in Light of the Opioid Crisis, 46 Fordham Urb. L.J. 683 (2019). Available at: https://ir.lawnet.fordham.edu/ulj/vol46/iss3/6 This Note is brought to you for free and open access by FLASH: The orF dham Law Archive of Scholarship and History. It has been accepted for inclusion in Fordham Urban Law Journal by an authorized editor of FLASH: The orF dham Law Archive of Scholarship and History. For more information, please contact [email protected]. WEANING DRUG MANUFACTURERS OFF THEIR PAINKILLER: CREATING AN EXCEPTION TO THE LEARNED INTERMEDIARY DOCTRINE IN LIGHT OF THE OPIOID CRISIS Max Roberts* Introduction ............................................................................................. 684 I. The Opioid Crisis and the Learned Intermediary Doctrine ........... 686 A. The Opioid Crisis .................................................................... 686 B. The Learned Intermediary Doctrine ..................................... 691 II. Fashioning an Opioid Exception to the Learned Intermediary Doctrine ............................................................................................
    [Show full text]
  • To Read the Lee County, VA Complaint
    VIRGINIA: IN THE CIRCUIT COURT OF LEE COUNTY LEE COUNTY, VIRGINIA Plaintiff, v. PURDUE PHARMA, L.P.; PURDUE PHARMA, INC.; THE PURDUE FREDERICK COMPANY, INC.; RHODES PHARMACEUTICALS, L.P.; ABBOTT LABORATORIES; ABBOTT LABORATORIES, INC.; MALLINCKRODT PLC; MALLINCKRODT LLC; ENDO HEALTH SOLUTIONS, INC; ENDO PHARMACEUTICALS, INC.; PAR Case No. CL18 - __________ PHARMACEUTICAL COMPANIES, INC.; PAR PHARMACEUTICAL, INC.; TEVA Jury Trial Demanded PHARMACEUTICALS USA, INC.; CEPHALON, INC.; BARR LABORATORIES, INC.; JANSSEN PHARMACEUTICALS, INC.; ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.; JANSSEN PHARMACEUTICA, INC.; WATSON LABORATORIES, INC.; ALLERGAN PLC; ACTAVIS PHARMA, INC.; ACTAVIS, LLC; INSYS THERAPEUTICS, INC.; KVK-TECH, INC.; AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC; AMNEAL PHARMACEUTICALS, INC.; AMNEAL PHARMACEUTICALS OF NEW YORK, LLC; MYLAN PHARMACEUTICALS, INC.; MCKESSON CORPORATION; MCKESSON MEDICAL-SURGICAL INC.; CARDINAL HEALTH, INC.; AMERISOURCEBERGEN DRUG CORPORATION; HENRY SCHEIN, INC.; GENERAL INJECTABLES & VACCINES, INC.; INSOURCE, INC.; CVS HEALTH CORPORATION; CVS PHARMACY, INC.; CVS TN DISTRIBUTION, L.L.C.; WALGREENS BOOTS ALLIANCE, INC.; WALGREEN CO.; EXPRESS SCRIPTS HOLDING COMPANY; EXPRESS SCRIPTS, INC; CAREMARK RX, L.L.C.; CAREMARKPCS HEALTH, L.L.C.; CAREMARK, L.L.C.; UNITEDHEALTH GROUP INCORPORATED; OPTUM, INC.; OPTUMRX, INC.; and DOES 1-100, Defendants. PLAINTIFF’S ORIGINAL COMPLAINT Plaintiff, Lee County, Virginia, by and through the undersigned attorneys, (hereinafter “Plaintiff,” “Lee County,” or “County”)
    [Show full text]
  • Big Pharma Takes on Marijuana Legalization: the Synthetic Marijuana Vs
    Emory University School of Law Emory Law Scholarly Commons Emory Corporate Governance and Accountability Review Perspectives Journals 1-1-2018 Big Pharma Takes On Marijuana Legalization: The Synthetic Marijuana vs. Botanical Marijuana Paradox Katharine Pickle Follow this and additional works at: https://scholarlycommons.law.emory.edu/ecgar-perspectives Recommended Citation Katharine Pickle, Big Pharma Takes On Marijuana Legalization: The Synthetic Marijuana vs. Botanical Marijuana Paradox, 5 Emory Corp. Governance & Accountability Rev. Perspectives 127 (2018). Available at: https://scholarlycommons.law.emory.edu/ecgar-perspectives/11 This Perspective is brought to you for free and open access by the Journals at Emory Law Scholarly Commons. It has been accepted for inclusion in Emory Corporate Governance and Accountability Review Perspectives by an authorized administrator of Emory Law Scholarly Commons. For more information, please contact law-scholarly- [email protected]. PICKLE GALLEYFINAL 2/20/2018 8:52 AM BIG PHARMA TAKES ON MARIJUANA LEGALIZATION: THE SYNTHETIC MARIJUANA VS. BOTANICAL MARIJUANA PARADOX INTRODUCTION As legalization of marijuana spreads across the U.S., stigmas related to the drug seem to be declining. In 2016, California, Nevada, and Massachusetts passed measures legalizing marijuana for recreational use and sale; while Florida, North Dakota and Arkansas legalized the use of only medical marijuana.1 The passage of these new laws brought the total number of states in which marijuana is legal in some form to 29; 7 states have legalized recreational use of marijuana, and 22 states have legalized only the medical use of marijuana.2 With marijuana remaining an illegal, Schedule I drug at the federal level, many legal questions and oddities surround the implications of federal law on state marijuana legalization.
    [Show full text]
  • 190605 Opioid Manufacturer Insys Therapeutics.Pdf
    Opioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global Resolution .. Page 1 of 4 ' ~ L rn[cri! :'lr:.ircs lJcparrmr-m ofJu~nn: T H UNJ · D S A" ES A O RNEY'S ( FI.C CENTRAL Dl _TRICifCALIFORNIA U.S. Attorneys » Central District of California » News Department of Justice U.S. Attorney's Office Central District of California FOR IMMEDIATE RELEASE Wednesday, June 5, 2019 Opioid Manufacturer Insys Therapeutics Agrees to Enter $225 Million Global Resolution of Criminal and Civil Investigations Company admits illegal conduct regarding promotion of Subsys, a powerful opioid painkiller LOS ANGELES - Opioid manufacturer lnsys Therapeutics agreed to a global resolution to settle the government's separate criminal and civil investigations, the Department of Justice announced today. As part of the civil resolution, lnsys agreed to pay $195 million to settle allegations that it violated the False Claims Act. As part of the criminal resolution, lnsys will enter into a deferred prosecution agreement with the government, lnsys's operating subsidiary will plead guilty to five counts of mail fraud, and the company will pay a $2 million fine and $28 million in forfeiture. Both the criminal and civil investigations stemmed from lnsys's payment of kickbacks and other unlawful marketing practices in connection with the marketing of Subsys. lnsys's drug Subsys is a sublingual fentanyl spray, a powerful, but highly addictive, opioid painkiller. In 2012, Subsys was approved by the Food and Drug Administration for the treatment of persistent breakthrough pain in adult cancer patients who are already receiving, and tolerant to, around-the­ clock opioid therapy.
    [Show full text]
  • U.S. V. Insys Therapeutics, Inc
    Case 1:19-cr-10191-RWZ Document 1 Filed 06/05/19 Page 1 of 11 FILED IN CLERKS OFFI CE UNITED STATES DISTRICT COURT DISTRICT OF MASSACI-IUSET).:$~ JUN - 5 PM 3: 36 UNITED STATES OF AMERICA ) 11 · · l N .S. DISTRICT COURT ) C 0 nmma · •:i~ TRl9, QF MASS. q V. ) ) Violations: \ l{CV' f 01 / INSYS THERAPEUTICS, INC., ) INSYS PHARMA, INC., ) Counts One-Five: Mail Fraud ) (18 U.S.C. §§ 1341) ) Defendants ) Forfeiture Allegation: ) (18 U.S.C. § 981(a)(l)(C) and ) 28 U.S.C. § 2461(c)) INFORMATION General Allegations At all times relevant to this Information: 1. Defendants Insys Therapeutics, Inc. and Insys Pharma, Inc. (collectively, "Defendants") are both Delaware corporations that maintain a principal place of business in Chandler, Arizona. At all times relevant to the Information, Insys Pharma, Inc. was a wholly­ owned subsidiary of Insys Therapeutics, Inc., and was its main operating subsidiary. 2. Defendants developed and own a drug called SUBSYS® (hereafter "Subsys"), a spray formulation of fentanyl to be applied under a patient's tongue (also called a sublingual spray). Fentanyl, a Schedule II controlled substance, and analogues of fentanyl were among the most potent opioids available for human use. The United States Food and Drug Administration ("FDA") approved Subsys in or about January 201 2 for the management of breakthrough pain in cancer patients 18 years of age or older who were already receiving and were tolerant to opioid therapy for their underlying persistent cancer pain. Subsys is in a category of drugs called Transmucosal Immediate Release Fentanyl ("TIRF") products, which includes other fentanyl­ based rapid onset opioids that competed with Subsys.
    [Show full text]